Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma

Hyung Soon Park, Hye Sun Lee, Ji Soo Park, Joon Seong Park, DongKi Lee, Se Joon Lee, Dong Sup Yoon, Min Goo Lee, Hei Cheul Jeung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O'Quigley method, and then analyzed in association with prognosis-overall survival (OS), using Cox's proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.

Original languageEnglish
Pages (from-to)1253-1263
Number of pages11
JournalCancer Research and Treatment
Volume48
Issue number4
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Adenocarcinoma
Survival
Carcinoembryonic Antigen
Pancreatic Neoplasms
Leukocyte Count
Proportional Hazards Models
Reference Values
Hemoglobins
Neutrophils
Multivariate Analysis
Lymphocytes
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, H. S., Lee, H. S., Park, J. S., Park, J. S., Lee, D., Lee, S. J., ... Jeung, H. C. (2016). Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. Cancer Research and Treatment, 48(4), 1253-1263. https://doi.org/10.4143/crt.2015.400
Park, Hyung Soon ; Lee, Hye Sun ; Park, Ji Soo ; Park, Joon Seong ; Lee, DongKi ; Lee, Se Joon ; Yoon, Dong Sup ; Lee, Min Goo ; Jeung, Hei Cheul. / Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. In: Cancer Research and Treatment. 2016 ; Vol. 48, No. 4. pp. 1253-1263.
@article{89346bedb33447368f70798cb90174fd,
title = "Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma",
abstract = "Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O'Quigley method, and then analyzed in association with prognosis-overall survival (OS), using Cox's proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.",
author = "Park, {Hyung Soon} and Lee, {Hye Sun} and Park, {Ji Soo} and Park, {Joon Seong} and DongKi Lee and Lee, {Se Joon} and Yoon, {Dong Sup} and Lee, {Min Goo} and Jeung, {Hei Cheul}",
year = "2016",
month = "1",
day = "1",
doi = "10.4143/crt.2015.400",
language = "English",
volume = "48",
pages = "1253--1263",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Park, HS, Lee, HS, Park, JS, Park, JS, Lee, D, Lee, SJ, Yoon, DS, Lee, MG & Jeung, HC 2016, 'Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma', Cancer Research and Treatment, vol. 48, no. 4, pp. 1253-1263. https://doi.org/10.4143/crt.2015.400

Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. / Park, Hyung Soon; Lee, Hye Sun; Park, Ji Soo; Park, Joon Seong; Lee, DongKi; Lee, Se Joon; Yoon, Dong Sup; Lee, Min Goo; Jeung, Hei Cheul.

In: Cancer Research and Treatment, Vol. 48, No. 4, 01.01.2016, p. 1253-1263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma

AU - Park, Hyung Soon

AU - Lee, Hye Sun

AU - Park, Ji Soo

AU - Park, Joon Seong

AU - Lee, DongKi

AU - Lee, Se Joon

AU - Yoon, Dong Sup

AU - Lee, Min Goo

AU - Jeung, Hei Cheul

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O'Quigley method, and then analyzed in association with prognosis-overall survival (OS), using Cox's proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.

AB - Purpose This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. Materials and Methods Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O'Quigley method, and then analyzed in association with prognosis-overall survival (OS), using Cox's proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. Results Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). Conclusion We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.

UR - http://www.scopus.com/inward/record.url?scp=84996757895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996757895&partnerID=8YFLogxK

U2 - 10.4143/crt.2015.400

DO - 10.4143/crt.2015.400

M3 - Article

C2 - 26875200

AN - SCOPUS:84996757895

VL - 48

SP - 1253

EP - 1263

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -